Expression of Β-Catenin and Cyclind1 in Biliary Tumors and Its Clinical Significance

WEN Quan,QIAO QI-lu,ZHAO Jian-xun,LIU Yu-cun
DOI: https://doi.org/10.3969/j.issn.1005-8982.2007.02.002
2007-01-01
Abstract:[Objective] To investigate expression of β-catenin and cyclinD1 and its possible role in the tumors' development and progression. [Methods] Expression of β-catenin and cyclinD1 was immunohistochemically studied in gallbladder carcinoma (33 cases), and cholangiocarcinoma (35 cases), respectively. The results were analyzed with clinical-pathological data. [Results] Normal expression of β-catenin and cyclinD1 was found in 10 cases of normal biliary control samples. Abnormal expression of β-catenin and cyclinD1 overexpression was detected in 48.5% (16/33) and 54.5% (18/33) in samples of gallbladder carcinoma respectively. Similarly, abnormal expression of β-catenin and cyclinD1 overexpression were also found in cholangiocarcinoma, 51.4% (18/35) and 45.7% (16/35) respectively.Abnormal expression of β-catenin and cyclinD1 overexpression were related to TNM stages and/or tumor differentiation in these biliary tumors. Furthermore, in both gallbladder carcinoma and cholangiocarcinoma, abnormal β-catenin expression was correlated with cyclinD1 overexpression (P <0.05). [ Conclusion] Abnormal expression of β-catenin and cyclinD1 overexpression exist in biliary tumors. Correlation between abnormal expression of β-catenin and cyclinD1 overexpression suggests that WNT/β-catenin signaling pathway plays a role in biliary tumors' development and progression.
What problem does this paper attempt to address?